Anti-cancer drug damages brain vessels

Feb 11, 2008

New research may help explain why an anti-cancer drug causes potentially fatal brain inflammation in certain patients. Scientists at Harvard Medical School mimicked the drug's activity in mice and found that it damaged the cell lining that prevents fluid from leaking from the spinal cord into the brain. The results will be published online on Feb. 11 in the Journal of Experimental Medicine.

The cancer drug Avastin (bevacizumab) is used to treat advanced bowel cancer in combination with chemotherapy. This drug targets a protein called VEGF (vascular endothelial growth factor) that stimulates blood vessel growth. Avastin inhibits the growth of tumors by cutting off their blood supply, which deprives them of oxygen and other nutrients.

In a small percentage of patients, however, Avastin can cause neurological side effects ranging from headaches and blurry vision to potentially fatal seizures and brain swelling.

The new study reveals that VEGF normally protects the specialized cells that create a seal between the brain and spinal column and thus prevent fluid from leaking into the brain. When VEGF was blocked in mice, these cells died and the animals developed brain swelling. The authors suspect that Avastin’s side effects in humans may be caused by a similar phenomenon. Why these symptoms occur in only a few patients is not yet known.

Source: Journal of Experimental Medicine

Explore further: FDA approves new drugs for irritable bowel syndrome

Related Stories

How bad can solar storms get?

10 minutes ago

Our sun regularly pelts the Earth with all kinds of radiation and charged particles. How bad can these solar storms get?

How we discovered the three revolutions of American pop

20 minutes ago

Dr Matthias Mauch discusses his recent scientific analysis of the "fossil record" of the Billboard charts prompted widespread attention, particularly the findings about the three musical "revolutions" that shaped the musical la ...

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.